The purpose of this study is to determine the effect of gender on pharmacodynamic interaction of propofol and dexmedetomidine, exploring the effect of gender on propofol unconsciousness median effective concentration with different dose dexmedetomidine.
60 cases male patients were randomly divided into four groups,and 60 female patients were also randomly divided into four groups.In each group, dexmedetomidine target plasma concentration are 0,0.4,0.6,0.8 ng/ml. Dexmedetomidine administered 15 min before target controlled infusion of propofol. The propofol infusion is started to provide a target effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness when the effect-site concentration and target concentration are equilibrium.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
Dexmedetomidine target plasma concentration is 0.0 ng/ml
Dexmedetomidine target plasma concentration is 0.4 ng/ml
Dexmedetomidine target plasma concentration is 0.6 ng/ml
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, China
the effect-site EC50 of propofol on loss of consciousness with different gender
The aim of the investigators study is to define the optimum target concentration (EC50) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.
Time frame: within 30 min during the induction of anesthesia
The EC95 of propofol for loss of consciousness with different gender
The aim of the investigators study is to define the optimum target concentration (EC95) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.
Time frame: within 30 min during the induction of anesthesia
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dexmedetomidine target plasma concentration is 0.8 ng/ml
The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness